Clinical diagnostics rely heavily on the detection and quantification of cancer biomarkers. The rapid detection of cancer-specific biomarkers is of great importance in the early diagnosis of cancers and plays a crucial role in the subsequent treatments. There are several different detection techniques available today for detecting cancer biomarkers. Because of target-related conformational alterations, high stability, and target variety, aptamers have received considerable interest as a biosensing system component. To date, several sensitivity-enhancement strategies have been used with a broad spectrum of nanomaterials and nanoparticles (NPs) to improve the limit and sensitivity of analyte detection in the construction of innovative aptasensors. The present article aims to outline the research developments on the potential of DNAzymes-based aptasensors for cancer biomarker detection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531510 | PMC |
| http://dx.doi.org/10.1186/s12951-022-01640-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of gene mutation and its expression in Brazilian pediatric B-ALL patients: clinical implications.
Front Pediatr
December 2024
Laboratory of Translational Research, Children's Hospital of Brasília, Brasília, Brazil.
Introduction: There is consistent evidence that may be a driver gene in B-ALL and that selected cases may benefit from the use of FLT3 inhibitors. Our study was conducted to evaluate the frequency and types of FLT3 mutations in pediatric patients with B-ALL, the relative expression of this gene, and their influence on clinical evolution.
Methods: We evaluated 156 children with B-ALL treated between July 2018 and September 2023.
To label or not: the need for validation in label-free imaging.
J Biomed Opt
June 2024
University of Wisconsin-Madison, Department of Biomedical Engineering, Madison, Wisconsin, United States.
Significance: Advances in label-free imaging have impacted many areas of biological and biomedical imaging ranging from cell biology and cancer to pathology and neuroscience. Despite the great progress and advantages of these methods, it is clear that to realize their full potential, validation by extrinsic labels and probes is critically needed.
Aim: This perspective calls for developing and applying innovative labels and probes to validate both existing and emerging label-free imaging methods.
CICADA: a circRNA effort toward the ghost proteome.
Nucleic Acids Res
December 2024
Binzhou People's Hospital Affiliated to Shandong First Medical University/College of Medical Information and Artificial Intelligence, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
Recent studies have confirmed that certain circRNAs encode proteins that are integral to various biological functions. In this study, we present CICADA, an algorithm specifically designed to assess the protein-coding potential and coding products of circRNAs at high throughput, which enables the identification of previously unknown circRNA-encoded proteins. By harnessing the potential of this algorithm, we identified a variety of functional, protein-coding circRNAs in esophageal squamous cell carcinoma and established circRNA translation profiles for diverse types of cancer.
View Article and Find Full Text PDFTumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?
Future Oncol
December 2024
Department of Hematology-Oncology, Université Saint-Joseph de Beyrouth, Beyrouth, Lebanon.
For the past few years, researchers and oncologists have been pushing to find biomarkers that would help predict which treatment option would best work on a patient. Tumor Mutational Burden (TMB) is one of the latest biomarkers that is being studied and considered as a promising agnostic immunotherapy biomarker. However, it still shows controversial results in studies due to the difficulty in finding solid comparable results.
View Article and Find Full Text PDF5-Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma.
Cancer Med
December 2024
Department of Hematology, Peking University First Hospital, Beijing, People's Republic of China.
Background: An effective urine-based method for the diagnosis, differential diagnosis and prognosis of multiple myeloma (MM) has not yet been developed. Urine cell-free DNA (cfDNA) carrying cancer-specific genetic and epigenetic aberrations may enable a noninvasive "liquid biopsy" for diagnosis and monitoring of cancer.
Methods: We first identified MM-specific hydroxymethylcytosine signatures by comparing 64 MM patients, 23 amyloidosis (AM) patients and 59 healthy cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!